Business
Block listing Interim Review
Block listing Interim Review.
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n27 August 2024\n \nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\n \nBlock Listing Interim Review\n \nAptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:\n \n \n\n\n\n\nName of Company\n\n\nAptamer Group plc\n\n\n\n\nName of Scheme\n\n\nThe Aptamer Group EMI Share Option Scheme\n\n\n\n\nPeriod of Return (from/to)\n\n\n25 February 2024 to 24 August 2024\n\n\n\n\nNumber and class of securities not issued at the start of the period under the scheme\n\n\n1,666,477 Ordinary Shares\n\n\n\n\nNumber of securities issued under the scheme during the period\n\n\n0\n\n\n\n\nBalance under the scheme of securities not yet issued at the end of the period\n\n\n1,666,477 Ordinary Shares\n\n\n\n\nNumber and class of securities originally admitted and the date of admission\n\n\n2,063,200 Ordinary Shares on 25 February 2022\n\n\n\n\nName of contact and telephone number\n\n\nAndrew Rapson +44 (0) 1904 217 404\n\n\n\n\n \n \n \n \n- ENDS -\n \nFor further information, please contact:\n \n\n\n\n\nAptamer Group plc\nDr Arron Tolley\n\n\n+44 (0) 1904 217 404\n\n\n\n\nSPARK Advisory Partners Limited - Nominated Adviser \nAndrew Emmott / Adam Dawes\n\n\n+44 (0) 20 3368 3550\n\n\n\n\nTurner Pope Investments (TPI) Limited - Broker \nJames Pope / Andrew Thacker\n\n\n+44 (0) 20 3657 0050\n\n\n\n\n \n \nAbout Aptamer Group plc\n \nAptamer develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.\n \nOptimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bio...